← Trials/Trial dossier/NCT00303277

CompletedPhase 4

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

Lead sponsor

Seattle Institute for Biomedical and Clinical Research

Assets

pravastatin / Simvastatin

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-90

Primary endpoint

•CSF abeta levels

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID21974

NCT IDNCT00303277

Timeline

Milestones

Study start2002-08 (month precision)

Primary completion2005-04actual (month precision)

Study completion2005-04actual (month precision)

Study first posted2006-03-16estimated

Last update posted2010-04-13estimated

Assets

Drug assets

pravastatin Simvastatin

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Total cholesterol > 200, and/or LDL > 130

•No cognitive impairment

•Statin-naive for at least one year

•Women must not be pregnant, nursing, or planning to become pregnant

Exclusion criteria

•Back ailments which would hinder LP procedure

•Neurological disease, including stroke, Parkinson's disease, Multiple Sclerosis, uncontrolled epilepsy, history of severe head trauma

•Hepatic disease

•Renal insufficiency

•Unstable medical disease

•Severe pulmonary disease

•Severe cardiac disease

•Uncontrolled hypertension (greater than 160/90)

•Uncontrolled hyper/hypothyroidism

•History of blood clotting abnormalities or platelet abnormalities

•History of chronic major psychiatric disorders or presence of current major depressive disorder (by DSM-IV criteria)

•History of substance abuse within the past year

•Taking exclusionary medications

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Amyloid biomarkers

Fluid / digital biomarkers

Amyloid biomarkers

1 endpoint

Primary/protocol endpoint

CSF abeta levels

Time frame:baseline and 12 weeks

descriptive

Fluid / digital biomarkers

1 endpoint

Secondary/protocol endpoint

CSF biomarkers

Time frame:baseline and 12 weeks

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.